In this edition, @nephroseeker.medsky.social breaks down the Bayesian voodoo behind removing evil humor www.nephjc.com/news/2026/sh... #EMIMCC #NephSky

🚨Another #NephJC short 🩳 FINE ONE: Finerenone in Type 1 Diabetes Fine, but does it cross the finish line? Blog by @nephromommy-akshu.bsky.social #NephSky #MedSky www.nephjc.com/news/2026/5/4/fineone

1/10 #NephJC #TenPost #NephSky In 2026 the only FDA approved 💊 for FSGS is sparsentan, an endothelin A/angiotensin II receptor inhibitor. Next up in the pipeline…transient receptor potential cation channel 6 (TRPC6) inhibitor (BI 764198) 🚰 Read the article 👇 www.pubmed.ncbi.nlm.nih.gov/41616795/

Do you struggle with FSGS? Are you a sparsentan fan but asking, what's next? TRPC6 inhibitors completed a phase 2 study! Are we closing in on a common pathway of FSGS pathology? Blog by @drsaivani.bsky.social & @sayalibthakare.bsky.social #NephSky #MedSky www.nephjc.com/news/trcpc6inhibition-fsgs

👂So, did you hear the one about avacopan and data manipulation? 🧮🧮🧮 @hswapnil.medsky.social has added onto our ADVOCATE summary with a "postscript" review of the controversies. #NephSky #MedSky www.nephjc.com/news/advocate?rq=avacopan

Gracias @dramiliflores.bsky.social, el resumen visual en espanol #NephSky #MedSky www.nephjc.com/news/2026/trpc6-spanish

💊FSGS precision medications started with AMKD (APOL-1) and inaxaplin. 💊This week we're discussing FSGS and what else is in the pipeline of therapeutics...TRPC6 inhibitors. #NephSky #MedSky Check out the VA by Dr. Divya Bajpai www.nephjc.com/news/2026/5/3/trpc6-inhibition-the-visual-abstract

⏰This opportunity has a GFR of zero after May 1st (11:59 pm EST)- NephJC's Editorial Internship is closing 😉 Last chance to apply #NephJC www.nephjc.com/news/nephjc-...

⏳ Deadline in a few days! Want to level up your science‑communication game? 👇👇Apply to the #NephJC Editorial Internship and help craft the conversations that move nephrology forward www.nephjc.com/news/nephjc-...

Still ordering hydralazine? 🤔 Beyond case reports, this large cohort compares hydralazine vs ACEi/ARB to estimate real-world vasculitis risk, will this 📉 bias & clarify the answer Read more 👇 pubmed.ncbi.nlm.nih.... #TenPostNephJC #NephJC #NephSky #MedSky

Hydralazine, a 1950s drug still used at the edges of modern care. Cheap? Available? Signal of benefit… shadowed by decades of immune toxicity signals 15 min to #TenPostNephJC #NephJC #NephSky #MedSky pubmed.ncbi.nlm.nih.gov/6786464/

Hydralazine is most classically associated with which serologic pattern in ANCA vasculitis? 25 min #TenPostNephJC #Nephsky #MedSky #NephJC A. High-titer PR3-ANCA B. High-titer MPO-ANCA C. ANCA− / anti-GBM+ D. anti-dsDNA antibodies

Check out the VA on hydralazine and population vasculitis risk by Dr. Divya Bajpai #NephSky www.nephjc.com/news/2026/4/hydralazine-anca-va

Do you prescribe hydralazine? Or, do you 🛑 it as soon as you see it? Hydralazine persists despite TID dosing & risks like... vasculitis 🔥 Are you asking Why-dralazine? ✅The blog by @dramiliflores.bsky.social @nephroseeker.medsky.social #NephSky www.nephjc.com/news/hydralazine-anca-vasculitis

#NephJC and @theisn.org Advancing Clinical Trials collab for #Nephtrials STEPS trial tests coordinated system-level intervention to improve preemptive kidney transplant 🗓️XSpce: April 10, 12pm EST ✍️Blog by @dramiliflores.bsky.social and @nephroseeker.medsky.social www.nephjc.com/news/steps-n...

0/10 Hey NephJC faithful, we are shaking it up. Given the 📉 attendance at live chats we’re changing to a summary 🧵& ❓ to answer, at your convenience. Still tag us #NephJC to get the discussion going! PS If we hear enough comments, we might bring chats back!😉

In jut 1 hour #NephJC is unveiling something new... #NephSky #MedSky

Hey #NephSky #MedSky 📣If you were planning on coming to the #NephJC chat on hyponatremia 4/7/26 at 9 pm...relax, we're trying something new (and it will be on Twitter and BlueSky)! www.nephjc.com/news/2026/4/7/regarding-the-situation-withsocial-media-in-general

📖Check out the latest @kireports.bsky.social community blog on slowing ADPKD from @thekidneywhisperer.bsky.social #NephSky #MedSky www.kireportscommunity.org/post/stoppin...

🧂Hyponatremia. We see it. We fix it. #NephJC But what if fixing the sodium… doesn’t fix the patient? The HIT trial challenges one of medicine’s most reflexive moves ✍️ By @brianrifkin.bsky.social www.nephjc.com/news/hyponat...

Do you have #FOMO from missing all the fun at #ISNWCN ? We've got you covered!! Check out the interview with @nephroseeker.medsky.social and @hswapnil.medsky.social discussing simultaneous publications at WCN in Yokohama, Japan #NephSky www.nephjc.com/news/conf-coverage

Hiponatremia el resumen visual, gracias @dramiliflores.bsky.social #NephSky #NephJC www.nephjc.com/news/2026/4/4/hiponatremia-el-resumen-visual

📉Low asymptomatic sodium in a hospitalized patient: Are you chill 🧊 or do you treat 🛠️ ? Next #NephJC 4/7/26, we're changing it up (let's see if anyone notices 👀) #NephSky VA by @brianrifkin.bsky.social www.nephjc.com/news/2026/4/4/hyponatremia-correction-the-visual-abstract

🚨 #NephJC short 🩳from @kidneyboy.bsky.social The PUSH trial! 😉Can a wink, a nudge & a push encourage kidney stone formers to drink more fluid to prevent recurrence 🪨? (Hint: have 💦 behavioral trials worked in CHF or PCKD?) #NephSky #MedSky www.nephjc.com/news/2026/4/2/nephjc-short-the-push-trial

Covering the world 🌐 @hswapnil.medsky.social @nephroseeker.medsky.social 🧑‍💻Reporting in from Yokohama, Japan #ISNWCN 🌸 📰Read all about the late breaking news #NephJC #NephSky www.nephjc.com/news/isnwcn-yokohama

The #ISNWCN has high trial impact clinical trials to celebrate latest and more successful results in our nephro world To celebrate the joy of getting together, and to #NephItForward, we officially opened up the #NephJC Editorial Internship application www.nephjc.com/news/nephjc-...

1/ Today’s #nephjc graduation was pure joy. Seeing mentors and interns from around the world come together reminded me why this community matters. ✨Thank you for making it extraordinary

1/10 Welcome to #TenPostNephJC Can we move beyond slowing CKD → to actually repairing the kidney? Last #NephJC we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.

Up next, we are taking a break on 03/24/26. Don’t forget to play NephMadness! www. ajkdblog.org/2026/03/01/welcome-to-nephmadness-2026/ We will return in April with WCN late breaking news. #NephJC Good night!

This is Dr. Sai Vani. It has been an honor to be your host tonight. I think all of us are celebrating WKD on March 12 and advocating for the importance of preventing kidney diseases and protecting planet Mother Earth. Goodbye until next time!

I sincerely thank all my #NephJC 2025-2026 interns! This is our last discussion. They are #FOAMed heroes. We could not do what we do without them. ♥️

Please thank your #NephJC 2025-2026 interns! This is their last discussion. They are #FOAMed heroes. We could not do what we do without them. ♥️

Please vote for the #NephJC kidneys! 🏆 Sign up for the newsletter to get a ballot. 2026 #NephJCKidneys vote begins — NephJC

if you want to support #NephJC and get some cool merch, check out www.nephjc.com/merch...#NephJC -

If you want to stay on top of #NephJC happenings, sign up for our once-a-week newsletter. www.nephjc.com/newsl...#NephJC

A heartfelt thank you to Brian,Christina and Swapnil for helping me with this beautiful script and to all of our mentors for the ongoing guidance and support! Brian Rifkin, @christina@nephroseeker.medsky.social, #NephJC

A sincere thank you to my #NephJC interim team members. Akshaya Jayachandran Bogdan Agavriloaei#NephJC@nataliaroxona.bsky.social

T3q Great discussion! #NephJC Do you think we are entering the era of remission, and dare I say it, cures for chronic kidney disease. Slowing progression is great, but regenerative treatments are the future! #NephJC

T3p What is the impact in pts with T1DM vs T2DM? This study included T1D but did not report results separately. FINEONE (nsMRA) study suggests similar pathology and benefits. Should T1D get their own study? #NephJC

T3o REACT currently requires a kidney biopsy for harvesting. Normally we don’t do biopsies in obvious DKD. Do you think that your pts with DKD will experience more serious adverse events related to biopsy if the phase 3 trial of rilparencel is positive? #NephJC

T3n Limitations #NephJC ⬇️Small number of pts Exclusion pts with severe CKD Not blinded Still determining optimal dosing and timing

T3m Based on the available data, would you consider enrolling patients with DKD in the phase 3 trial of rilparencel? Are there any patients you would advise not to participate? Do you think REACT will be a viable option in 5-10 years? #NephJC

T3l Various studies are in the pipeline; some are completed, some are recruiting, and the majority of the studies are in the US. #NephJC

T3k There are many potential advantages of REACT over RRT & transplant. Many pts would like to be able to regenerate their own tissue to prevent organ failure, and/or exposure to lifelong immunosuppression. Pts who don’t qualify for transplant might still get rilparencel. #NephJC

T3j Current research is limited by a selection of pts at different CKD stages & different etiologies. Only a few trials, such as the REACT studies, specifically target DKD. Distinct types of kidney damage may affect the efficacy of the treatment. #NephJC

T3i Various studies done with different cell lines in patients with AKI and CKD have been attempted, including stem cells and progenitor cells. These studies are not without controversy, and unfortunately incorporate many elements that may lead to bias in observations. #NephJC

T3h The 2ary endpoints were less insightful due to the limited number of events, & short study. Most 2ary endpoints required a sig change in eGFR or UPCR. Notably, the probability of not meeting the end point was ≥80% for both cohorts through the 18-months. #NephJC

T3g In this small study that received 2 doses of REACT the effect was more impressive on GFR slope than SGLT2/GLP1 with only 1.16-1.24 ml/min/1.73m2/year reduction. If phase 3 trials show similar results, where do you see REACT being used (adjuvant or primary treatment)? #NephJC

T3f Do you think that if we implemented GDMT in a majority of DKD patients that we would even need/consider the use of REACT rilparencel infusions? Is there a high risk group that might benefit significantly from this treatment? Perhaps genetics will be the clue? #NephJC

T3e Pts received kidney protective medications: 💊80% ACEi 💊37% SGLT2i 💉39% GLP-1 RA SGLT2i and GLP-1 RA had less administration because of the lack of CKD guidelines during the period of the study, still these are higher than the general US population. #NephJC